These sites bind to coreceptor CCR5 or CXCR4 on the membrane of the host cell (center panel), an event that initiates steps that culminate in the fusion of the HIV envelope with the host cell ...
Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback